Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 7/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1363412 | 1.00 | SLC6A4 (0.36) | SLC6A4MAPK1LMNABCL2SLC6A2 | |
| SCHEMBL4478902 | 0.95 | SLC6A4 (0.37) | SLC6A4MAPK1LMNABCL2SLC6A2 | |
| SCHEMBL5430929 | 0.92 | SLC6A4 (0.37) | SLC6A4MAPK1LMNABCL2SLC6A2 | |
| SCHEMBL13987721 | 0.89 | SLC6A4 (0.40) | SLC6A4MAPK1LMNABCL2SLC6A2 | |
| SCHEMBL1361477 | 0.88 | SLC6A4 (0.37) | SLC6A4MAPK1LMNABCL2SLC6A2 | |
| SCHEMBL1360618 | 0.85 | BCL2 (0.41) | SLC6A4MAPK1LMNABCL2SMN1; SMN2 | |
| SCHEMBL1363451 | 0.83 | BCL2 (0.36) | SLC6A4MAPK1LMNABCL2SLC6A2 | |
| SCHEMBL1363409 | 0.83 | SLC6A4 (0.36) | SLC6A4MAPK1LMNABCL2SLC6A2 | |
| SCHEMBL13987921 | 0.83 | BCL2 (0.37) | SLC6A4MAPK1LMNABCL2SLC6A2 | |
| SCHEMBL679 | 0.82 | BCL2 (0.42) | SLC6A4MAPK1LMNABCL2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067640-B2 | Method for the separation of intermediates which may be used for the preparation of escitalopram | H. LUNDBECK A/S (DK) | 2011-11-29 | — | — | US | disclosed |
| US-20110065937-A1 | METHOD FOR THE SEPARATION OF INTERMEDIATES WHICH MAY BE USED FOR THE PREPARATION OF ESCITALOPRAM | H. LUNDBECK A/S (DK) | 2011-03-17 | — | — | US | disclosed |
| US-7582780-B2 | Method for the separation of intermediates which may be used for the preparation of escitalopram | H. LUNDBECK A/S (DK) | 2009-09-01 | — | — | US | disclosed |
| EP-1716108-B1 | METHOD FOR THE SEPARATION OF INTERMEDIATES WHICH MAY BE USED FOR THE PREPARATION OF ESCITALOPRAM | LUNDBECK & CO AS H (DK) | 2008-10-15 | — | — | EP | disclosed |
| US-20070190624-A1 | Method for the separation of intermediates which may be used for the preparation of escitalopram | H. LUNDBECK A/S (DK) | 2007-08-16 | — | — | US | disclosed |
| US-20070129561-A1 | Method for the separation of intermediates which may be used for the preparation of escitalopram | H. LUNDBECK A/S (DK) | 2007-06-07 | — | — | US | disclosed |
| EP-1716108-A1 | METHOD FOR THE SEPARATION OF INTERMEDIATES WHICH MAY BE USED FOR THE PREPARATION OF ESCITALOPRAM | H. Lundbeck A/S (DK) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005077891-A1 | METHOD FOR THE SEPARATION OF INTERMEDIATES WHICH MAY BE USED FOR THE PREPARATION OF ESCITALOPRAM | H. LUNDBECK A/S (DK) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065937-A1 | METHOD FOR THE SEPARATION OF INTERMEDIATES WHICH MAY BE USED FOR THE PREPARATION OF ESCITALOPRAM | MAOB, HSD17B14, MAOA | SLC6A4 39/4885MAPK1 3648/4885LMNA 2746/4885 |
| US-20070129561-A1 | Method for the separation of intermediates which may be used for the preparation of escitalopram | MAOB, HSD17B14, MAOA | SLC6A4 39/4885MAPK1 3648/4885LMNA 2746/4885 |
| US-20070190624-A1 | Method for the separation of intermediates which may be used for the preparation of escitalopram | MAOB, HTR4, HTR2B | SLC6A4 6/4885MAPK1 3771/4885LMNA 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.